{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:04:53Z","timestamp":1766073893885,"version":"3.48.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["169148"],"award-info":[{"award-number":["169148"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Systemically administered anticancer vascular endothelial growth factor inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal vascular endothelial growth factor levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept versus ranibizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This population-based new-user active-comparator cohort study in Ontario, Canada, evaluated 44,571 patients aged 66 years and older, newly treated with intravitreal aflibercept or ranibizumab between August 1, 2015, and July 31, 2019. The risk of adverse renal outcomes was compared while controlling for baseline and time-varying covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The composite renal outcome occurred in 12.0% (1,778\/14,863) of aflibercept recipients versus 10.0% (1,327\/13,289) of ranibizumab recipients (relative risk: 1.00, 95% CI: 0.93\u20131.06 at the 5-year follow-up). No significant differences were observed across retinal disease subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Intravitreal aflibercept and ranibizumab carry comparable risks of renal adverse events despite their distinct systemic pharmacodynamics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004653","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:01:20Z","timestamp":1757444480000},"page":"187-194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["KIDNEY INJURY DURING TREATMENT WITH AFLIBERCEPT VERSUS RANIBIZUMAB"],"prefix":"10.1097","volume":"46","author":[{"given":"Robert J.","family":"Campbell","sequence":"first","affiliation":[{"name":"ICES, Kingston and Toronto, Ontario, Canada;"},{"name":"Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada;"},{"name":"Department of Ophthalmology, Kingston Health Sciences Centre, Hotel Dieu Hospital site, Kingston, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif R.","family":"El-Defrawy","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Department of Ophthalmology, Kensington Eye Institute, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep S.","family":"Gill","sequence":"additional","affiliation":[{"name":"ICES, Kingston and Toronto, Ontario, Canada;"},{"name":"Division of Geriatric Medicine, Queen's University, Kingston, Ontario, Canada;"},{"name":"Division of Geriatric Medicine, Providence Care Hospital, Kingston, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Shellenberger","sequence":"additional","affiliation":[{"name":"ICES, Kingston and Toronto, Ontario, Canada;"},{"name":"Queen's University, Kingston, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlo","family":"Whitehead","sequence":"additional","affiliation":[{"name":"ICES, Kingston and Toronto, Ontario, Canada;"},{"name":"Queen's University, Kingston, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaim M.","family":"Bell","sequence":"additional","affiliation":[{"name":"ICES, Kingston and Toronto, Ontario, Canada;"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Department of Medicine, Sinai Health System, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Bronskill","sequence":"additional","affiliation":[{"name":"ICES, Kingston and Toronto, Ontario, Canada;"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Michael","family":"Paterson","sequence":"additional","affiliation":[{"name":"ICES, Kingston and Toronto, Ontario, Canada;"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"McIsaac","sequence":"additional","affiliation":[{"name":"School of Mathematical and Computational Sciences, University of Prince Edward Island, Charlottetown, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251218","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R2-20251218","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-20251218","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20251218","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"R5-20251218","first-page":"73","article-title":"Targeted therapy for metastatic colorectal cancer: role of aflibercept","volume":"12","author":"Mitchell","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"R6-20251218","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"R7-20251218","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R8-20251218","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ophtha.2018.01.019","article-title":"Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema","volume":"125","author":"Jampol","year":"2018","journal-title":"Ophthalmology"},{"key":"R9-20251218","doi-asserted-by":"crossref","first-page":"e113701","DOI":"10.1371\/journal.pone.0113701","article-title":"Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys","volume":"9","author":"Tschulakow","year":"2014","journal-title":"PLoS ONE"},{"key":"R10-20251218","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence","volume":"96","author":"Hanna","year":"2019","journal-title":"Kidney Int"},{"key":"R11-20251218","doi-asserted-by":"crossref","first-page":"579603","DOI":"10.3389\/fmed.2020.579603","article-title":"Thrombotic microangiopathy and acute Kidney Injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med"},{"key":"R12-20251218","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.2169\/internalmedicine.5410-20","article-title":"Nephrotic syndrome with focal segmental glomerulosclerosis induced by intravitreal injections of vascular endothelial growth factor inhibitor","volume":"59","author":"Kakeshita","year":"2020","journal-title":"Intern Med"},{"key":"R13-20251218","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","article-title":"Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy","volume":"13","author":"Shye","year":"2020","journal-title":"Clin Kidney J"},{"key":"R14-20251218","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"R15-20251218","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.ophtha.2012.05.043","article-title":"Subspecialization in glaucoma surgery","volume":"119","author":"Campbell","year":"2012","journal-title":"Ophthalmology"},{"key":"R16-20251218","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ophtha.2012.05.028","article-title":"Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis","volume":"119","author":"Campbell","year":"2012","journal-title":"Ophthalmology"},{"key":"R17-20251218","doi-asserted-by":"crossref","first-page":"e4203","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"key":"R18-20251218","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ophtha.2006.08.036","article-title":"Surgeon volumes and selected patient outcomes in cataract surgery A population-based analysis","volume":"114","author":"Bell","year":"2007","journal-title":"Ophthalmology"},{"key":"R19-20251218","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1001\/jama.2009.683","article-title":"Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery","volume":"301","author":"Bell","year":"2009","journal-title":"JAMA"},{"key":"R20-20251218","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"R22-20251218","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"key":"R23-20251218","doi-asserted-by":"crossref","first-page":"e001821","DOI":"10.1136\/bmjopen-2012-001821","article-title":"Validity of the International Classification of Diseases, Tenth Revision code for acute kidney injury in elderly patients at presentation to the emergency department and at hospital admission","volume":"2","author":"Hwang","year":"2012","journal-title":"BMJ open"},{"key":"R24-20251218","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"R25-20251218","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/sim.2328","article-title":"A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use","volume":"25","author":"Austin","year":"2006","journal-title":"Stat Med"},{"key":"R26-20251218","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-Year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R27-20251218","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R28-20251218","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jclinepi.2008.08.005","article-title":"Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials","volume":"62","author":"Tsang","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R29-20251218","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1745-6215-13-138","article-title":"Drug safety assessment in clinical trials: methodological challenges and opportunities","volume":"13","author":"Singh","year":"2012","journal-title":"Trials"},{"key":"R30-20251218","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"R31-20251218","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"R32-20251218","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"R33-20251218","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"R34-20251218","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:34Z","timestamp":1766073634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004653"}},"subtitle":["A Population-Based Study"],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004653","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"type":"print","value":"0275-004X"},{"type":"electronic","value":"1539-2864"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}